




The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 9.5% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 84% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	4,075
Cost of Goods Sold	0
Intangible Assets	2,260
Liabilities, Current	1,463
Liabilities, Non-Current	915
Other Assets	735
Other Compr. Net Income	0
Other Expenses	3,161
Other Liabilities	0
Other Net Income	-224
Other Revenues	0
Property and Equipment	138
Research and Development	85
Selling, General and Administrative Expense	6,875

Output Variable	Value in 1000 USD
Assets	7,208
Liabilities	2,378
Expenses	10,121
Revenues	0
Stockholders Equity	4,830
Net Income	-10,345
Comprehensive Net Income	-10,345
BaseVar	9,966
ECR before Limited Liability	3.8%
Economic Capital Ratio	145%